Effect of RAS inhibitors in left ventricular remodeling after transcatheter aortic valve implantation: a multicenter randomized controlled trial

RAS inhibitors after transcatheter aortic valve implantation

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100042266

Enrollment

Unknown

Registered

2021-01-17

Start date

2021-01-18

Completion date

Unknown

Last updated

2021-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aortic stenosis

Interventions

control group:No RASi

experimental group:Fosinopril

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Aged > 60 years; (2) symptomatic severe aortic stenosis; (3) heart failure with at least NYHA I; (4) LVEF >= 40%.

Exclusion criteria

Exclusion criteria: (1) Other valve diseases require intervention; (2) Fosinopril cannot tolerate; (3) A history of vasogenic edema; (4) Symptomatic hypotension and/or systolic blood pressure 5.4mmol/L; (9) Place CRT before or after operation; (10) Unsuccessful valve implantation; (11) Failure to complete follow-up as required.

Design outcomes

Primary

Measure	Time frame
LV mass index;	—

Secondary

Measure	Time frame
mortality;readmission with heart failure;NT-ProBNP;NYHA;KCCQ score;6MWT;	—

Countries

China

Contacts

Public ContactMao Chen

West China Hospital, Sichuan University

hmaochen@vip.sina.com+8618980602046

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026